Navigation Links
Shire to Introduce a New UK Listed Holding Company
Date:4/14/2008

ve the same Board and management team as Shire and there will be no substantive changes to corporate governance and investor protection measures. As is the case for Shire, Shire Limited will have its primary listing on the London Stock Exchange and, upon listing, will be included in FTSE's UK Index Series. Shire Limited also intends that its American Depositary Shares will be traded on NASDAQ, in place of Shire's existing ADS program.

Annual General Meeting

Assuming the Scheme becomes effective, this year's annual general meeting for the Shire group will be an annual general meeting of Shire Limited which is expected to be held in September.

Terms of the Scheme

Under the terms of a scheme of arrangement pursuant to sections 895 to 899 of the UK Companies Act 2006 (the "Scheme"), Shire Limited will issue Shire Limited ordinary shares to holders of Shire ordinary shares on a one-for-one basis. The Proposals do not involve any payment for the new ordinary shares.

The effect of the Proposals will therefore be as follows:

- Shire will become a subsidiary of Shire Limited (Shire Limited will be listed on the LSE in Shire's place);

- each Shire ordinary shareholder will own an identical number of new ordinary shares in Shire Limited as was owned in Shire; and

- Shire Limited's share capital will subsequently be reduced by a Jersey Court process to create distributable reserves.

It is expected that a Circular setting out full details of the Proposals will be sent to shareholders tomorrow, 16th April, 2008. A prospectus in relation to Shire Limited (the "Prospectus") will also be published and both documents will be available on Shire's website, http://www.shire.com.

ADS Holders

The ordinary shares underlying Shire ADSs will participate in the Scheme, if approved, like all other ordinary shares in Shire. In conjunction with the Scheme, Shire ADSs will
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
2. Shire plc: Long Term Incentive Plan
3. Shire plc: IFRS Results for the Year Ending December 31, 2007
4. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
5. Shire plc: Correction Re Website
6. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
7. Shire Engages Palio
8. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
11. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Junction, MD (PRWEB) July 28, 2014 ... in personalized medicine, will be exhibiting data and research ... year’s International Spine Intervention Society’s (ISIS) 22nd ... 30th-August 3rd, at the Hyatt Regency, in Orlando, Florida. ... the knowledge and clinical competence of physicians who care ...
(Date:7/28/2014)... According to the ... Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, Environmental, ... - Global Forecasts to 2019" published by ... at $896.5 Million in 2014 and is ... growing at a CAGR of 5.9% from ...
(Date:7/28/2014)... Wis. , July 28, 2014   Propeller ... respiratory disease, announced the hire of Brad Towle ... Towle will be responsible for driving the company,s sales ... broad experience in healthcare, and specifically his past role ... insight to the company at this pivotal time in ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... Feb. 28 InterMune, Inc.,(Nasdaq: ITMN ) ... Officer of InterMune, will present at Susquehanna,s Second ... on March 5, 2008,at 2:30 p.m. EST., ... presentation, investors and other,interested parties may log on ...
... ... Feb. 28 Cepheid (Nasdaq:,CPHD) today announced financial results for the fourth quarter and full,year ... Total revenues of $129.5 million, a 48 percent increase from $87.4 ... - Total product sales of $116.5 million, a 41 percent increase from ...
... N.C., Feb. 28 PPD, Inc. (Nasdaq:,PPDI) today ... (NDA) for alogliptin, a highly selective DPP-4 inhibitor ... accepted for filing by the U.S.,Food and Drug ... Under PPD,s agreement with Takeda, the FDA,s ...
Cached Biology Technology:InterMune to Present at the SIGnificant Options in Healthcare Conference 2Cepheid Reports Fourth Quarter and Full Year 2007 Results 2Cepheid Reports Fourth Quarter and Full Year 2007 Results 3Cepheid Reports Fourth Quarter and Full Year 2007 Results 4Cepheid Reports Fourth Quarter and Full Year 2007 Results 5Cepheid Reports Fourth Quarter and Full Year 2007 Results 6Cepheid Reports Fourth Quarter and Full Year 2007 Results 7Cepheid Reports Fourth Quarter and Full Year 2007 Results 8Cepheid Reports Fourth Quarter and Full Year 2007 Results 9Cepheid Reports Fourth Quarter and Full Year 2007 Results 10Cepheid Reports Fourth Quarter and Full Year 2007 Results 11Cepheid Reports Fourth Quarter and Full Year 2007 Results 12Cepheid Reports Fourth Quarter and Full Year 2007 Results 13Cepheid Reports Fourth Quarter and Full Year 2007 Results 14PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration 2
(Date:7/28/2014)... 2014)The Brain & Behavior Research Foundation today announced ... Prizes, recognizing exceptional clinical and basic research by ... Young Investigator Grants. The grants enable early career ... psychosocial research for the prevention, early detection, treatment, ... in four people. , Six young scientistswinners of ...
(Date:7/28/2014)... from fertility problems, many of these due to genetic ... expect such genes, which reduce an individual,s ability to ... Weizmann Institute of Science that recently appeared in ... Not only can it explain the high rates of ... understanding the causes of genetic diseases and their treatment. ...
(Date:7/27/2014)... that nicotine and cotinine, a metabolite of nicotine, can ... in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is ... ends up in the tobacco smoke. Once inhaled, it ... is activated by a variety of enzymes called Cytochrome ... nicotine can partially interfere with the activation of NNK, ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Mutations from Venus, mutations from Mars 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... Pathological gambling can be successfully treated with medications ... researchers at the annual meeting of the American ... outcomes in gamblers treated with medications often used ... pathological gambling disorder will continue their gambling behavior ...
... well-known for his book On the Origin of Species, in ... contributed to many specific fields within biology. As the ... December issue of the American Journal of Botany ... Darwin, Darwin,s contributions to botany, and what scientists have discovered ...
... across the vast expanses of the ocean to attract potential ... decades, and a scientist at Scripps Institution of Oceanography at ... be good news for the population of the endangered marine ... with John Hildebrand of Scripps Oceanography and Sarah Mesnick of ...
Cached Biology News:Pathological gambling may be successfully treated with medications for substance addiction 2Charles Darwin: More than the origin 2Charles Darwin: More than the origin 3The pitch of blue whale songs is declining around the world, scientists discover 2The pitch of blue whale songs is declining around the world, scientists discover 3
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
... new Hummingbird has the ability to quickly and ... makes it a perfect candidate for inclusion in ... OCX interface supplied with all the Cartesian products ... Hummingbirds ability to copy plates in seconds ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... Tracker Intracellular Localization Kit with TransIT-siQUEST ... approach to directly label and deliver ... efficient yet non-destructive manner, for in ... functional inhibition of target gene expression ...
Biology Products: